- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07635888
Silent Aspiration Following Extubation in the ICU (SAFE-ICU)
Incidence, Risk Factors, and Outcomes of Silent Aspiration Post Extubation in the ICU
Post-extubation dysphagia is common in critically ill patients and may lead to silent aspiration, which often remains undetected because patients do not exhibit overt clinical signs such as coughing or choking. Current bedside nursing swallow screening may fail to identify silent aspiration in patients recovering from prolonged mechanical ventilation.
The goal of this observational study is to learn about the incidence, risk factors, and clinical outcomes of silent aspiration in critically ill adult patients who require prolonged mechanical ventilation and are extubated in the ICU. The main questions it aims to answer are:
- How often does silent aspiration occur in ICU patients intubated for 5 days or longer after extubation?
- Can silent aspiration be present despite passing the routine bedside nursing swallow screen?
- What clinical factors are associated with silent aspiration?
- Is silent aspiration associated with worse clinical outcomes such as aspiration pneumonia, reintubation, prolonged ICU stay, ventilator-free days, or mortality? Participants who have been mechanically ventilated for 5 days or more will undergo routine bedside swallow screening followed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES), considered the gold-standard diagnostic tool for detecting silent aspiration, within 72 hours after extubation. Researchers will compare bedside nursing swallow screening results with FEES findings to evaluate the diagnostic accuracy of bedside screening in detecting silent aspiration. Clinical data, swallowing assessment findings, and patient outcomes will also be collected and analyzed.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Background:
Post-extubation dysphagia (PED) is common in critically ill patients and is often multifactorial in origin, resulting from trauma, neuromuscular weakness, altered sensation, impaired cognition, and desynchronized breathing-swallowing coordination. Silent aspiration - defined as entry of oropharyngeal material below the vocal folds without overt clinical signs such as coughing or choking - has been reported in up to 69.3% of ICU patients undergoing instrumental assessment. Despite this, current clinical practice at many centers does not mandate instrumental swallow evaluation for patients who pass routine bedside nursing swallow screening.
Study Design:
This is a prospective observational study conducted in the ICU at Cleveland Clinic Abu Dhabi (CCAD). Informed consent will be obtained from all patients or their next of kin prior to enrollment.
Participants:
Adult ICU patients who have been mechanically ventilated for 5 or more days and are subsequently extubated will be eligible for enrollment. Exclusion criteria include: (1) tracheostomy; (2) do-not-reintubate orders; (3) pregnancy; and (4) absence of informed consent.
Procedures:
All enrolled patients will undergo the standard bedside nursing swallow screen per institutional protocol (CCAD PolicyTech). For the purpose of this study, Fiberoptic Endoscopic Evaluation of Swallowing (FEES) will be performed in all enrolled patients up to 72 hours of extubation, regardless of bedside screening results. FEES is a well-established, safe, and portable instrumental assessment that allows direct visualization of pharyngeal and laryngeal structures and detection of aspiration, including silent aspiration. FEES will only be performed after approval by the treating attending physician, and patients with contraindications (e.g., high bleeding risk, high oxygen requirements) will be excluded from the procedure.
Assessments:
FEES findings will be reported using standardized validated scales including the Penetration-Aspiration Scale (PAS), Dysphagia Severity Rating Scale (DSRS), Pharyngeal Residue Severity Rating Scale (PRSS), Murray Secretion Scale, and Airway Protection Scale. Clinical data collected will include age, sex, admitting diagnosis, reasons for intubation, duration of mechanical ventilation, oxygen requirements, bedside swallow screen findings, and clinical outcomes including aspiration pneumonia, reintubation, ventilator-free days, ICU and hospital length of stay, and mortality.
Statistical Analysis:
Descriptive statistics will be used to report the incidence of silent aspiration. Diagnostic accuracy (sensitivity, specificity, Cohen's kappa) of bedside nursing screening will be calculated using FEES as the reference standard. Multivariable logistic regression will identify independent predictors of silent aspiration and its association with clinical outcomes. A minimum sample of 274 patients will be recruited (based on an expected 20% incidence, 95% CI, 5% margin of error, 10% loss to follow-up).
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jihad Mallat, MD, PhD
- Número de teléfono: +97125019000
- Correo electrónico: mallatj@ccad.ae
Ubicaciones de estudio
-
-
-
Abu Dhabi, Emiratos Árabes Unidos
- Cleveland Clinic Abu Dhabi
-
Contacto:
- Jihad Mallat, MD PhD
- Número de teléfono: +97125019000
- Correo electrónico: mallatj@ccad.ae
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Adult ICU patients requiring invasive mechanical ventilation for 5 days or longer
- Successful extubation after invasive mechanical ventilation
- Undergoing bedside nursing swallow screening after extubation
- Ability to undergo Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation
- Provision of informed consent by the patient or legally authorized representative
Exclusion Criteria:
- Presence of tracheostomy
- Do-not-reintubate orders/Allow natural death
- Pregnancy
- Absence of informed consent
- Contraindication to FEES as determined by the treating physician (e.g., high bleeding risk or severe oxygen requirements)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
ICU Patients Following Prolonged Mechanical Ventilation
Adult ICU patients intubated for 5 days or longer undergoing bedside swallow screening and Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation to assess silent aspiration
|
FEES will be performed within 72 hours after extubation to assess swallowing function and detect silent aspiration in ICU patients following prolonged mechanical ventilation.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Silent Aspiration After Extubation
Periodo de tiempo: Up to 72 hours after extubation
|
Silent aspiration identified by Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in ICU patients intubated for 5 days or longer after extubation
|
Up to 72 hours after extubation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Diagnostic Accuracy of Bedside Swallow Screening
Periodo de tiempo: Up to 72 hours after extubation
|
Sensitivity and specificity of bedside nursing swallow screening for detecting silent aspiration using FEES as the reference standard
|
Up to 72 hours after extubation
|
|
Aspiration Pneumonia
Periodo de tiempo: Up to 30 days after extubation
|
Incidence of aspiration pneumonia following extubation
|
Up to 30 days after extubation
|
|
Reintubation
Periodo de tiempo: Up to 30 days after extubation
|
Need for reintubation after extubation
|
Up to 30 days after extubation
|
|
Ventilator-Free Days
Periodo de tiempo: 28 days
|
Number of ventilator-free days after extubation
|
28 days
|
|
ICU Length of Stay
Periodo de tiempo: Up to 24 weeks
|
Length of ICU stay after extubation
|
Up to 24 weeks
|
|
Hospital length of stay
Periodo de tiempo: Up to 26 weeks
|
Total hospital length of stay
|
Up to 26 weeks
|
|
ICU Mortality
Periodo de tiempo: Up to 24 weeks
|
Death occurring during ICU stay
|
Up to 24 weeks
|
|
Hospital Mortality
Periodo de tiempo: Up to 26 weeks
|
Death occurring during hospitalization
|
Up to 26 weeks
|
|
Risk Factors Associated With Silent Aspiration
Periodo de tiempo: Up to 26 weeks
|
Clinical factors independently associated with silent aspiration identified using multivariable analysis
|
Up to 26 weeks
|
|
Duration of Dysphagia
Periodo de tiempo: Up to 3 months
|
Duration of post-extubation dysphagia identified by FEES
|
Up to 3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jihad Mallat, MD, PhD, Cleveland Clinic Abu Dhabi
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Atributos de la enfermedad
- Infecciones del Tracto Respiratorio
- Infecciones
- Enfermedades de las vías respiratorias
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades pulmonares
- Enfermedades esofágicas
- Neumonía
- Enfermedades Otorrinolaringológicas
- Enfermedades faríngeas
- Condiciones Patológicas, Signos y Síntomas
- Enfermedad crítica
- Trastornos de la deglución
- Neumonía, Aspiración
Otros números de identificación del estudio
- A-2026-026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .